In comparison, using the 2015 WHO guidelines,31 valid at the time of the study, to determine treatment eligibility (APRI score>2; or ALT levels above 30 IU/L for men/above 19 IU/L for women and HBV DNA levels>20 000 IU/mL; or presence of HIV co-infection), a total of 33/62 (53.2%) were eligible, 25/33 (75.8%) due to HIV co-infection. The gene discussed is GPT; the disease is coinfection.